| Date | Title | Description |
| 27.08.2026 | CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum | CS2009 Achieved Key Clinical Validations for Efficacy and Safety
As of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the d... |
| 07.08.2026 | LigaChem Gains Sole Control of B7-H4 Cancer Drug With Distinct Tumor-Killing Mechanism | By Donald C. Case
Published: Aug 07 2026, 2:29 PM EDT
Share on Facebook Share on Twitter Share on LinkedIn Share on Reddit Share on Flipboard |
| 25.06.2026 | CStone Pharmaceuticals Enters into Exclusive Commercialization Agreement with Arrotex for Sugemalimab across Australia and New Zealand | Arrotex, the pharmaceutical commercialization platform of DBG, Australia's leading diversified healthcare group, will be responsible for the registration, market access, and commercialization of sugemalimab in Australia and New Zealand.
Thi... |
| 11.06.2026 | CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) ASCO 2026 Key Highlights | SUZHOU, China, June 11, 2026 /PRNewswire/ -- The clinical datasets presented at ASCO 2026 by CStone further validate the trispecific synergistic mechanism of CS2009 and support its potential to become a next-generation immuno-oncology (I/O)... |
| 01.06.2026 | ASCO 2026 | CStone Presents Updated Clinical Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody), Reinforcing Triple-Target Synergy and Delivering Strong Proof-of-Concept | First-line NSCLC – Compelling Activity Across All PD-L1 Subgroups
In first-line non-small cell lung cancer (NSCLC) patients with high PD-L1 expression (TPS ≥50%), CS2009 monotherapy achieved an objective response rate (ORR) of 81.3% and a d... |
| 20.04.2026 | CStone Presented Preclinical Data for Three Novel or Differentiated ADCs at AACR 2026, Including CS5007 (EGFR/HER3) | SUZHOU, China, April 20, 2026 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, immunology, inflammatio... |
| 26.03.2026 | CStone Announces 2025 Annual Results: Accelerated Expansion of Global Commercial Footprint and Efficient Advancement of Innovation Pipeline 2.0 | Rapid Advancement Across Core R&D Pipeline
The global, multicenter Phase I/II clinical trial of CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) is actively enrolling patients in Australia and China, and the Phase II IND application has b... |
| 26.03.2026 | CStone Updated Clinical Progress and Key Phase I/II Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) | Key Highlights:
Excellent Safety Profile: As of mid-March 2026, 113 heavily pretreated patients with solid tumors have been enrolled in the Phase I trial of CS2009, with a median follow-up of approximately 6 months. The more mature data con... |
| 23.02.2026 | CStone Announces MHRA Approval in UK for Sugemalimab in Stage III NSCLC | Following approval by the European Commission (EC), sugemalimab has received a new indication approval from the UK Medicines and Healthcare products Regulatory Agency (MHRA) for stage III non-small cell lung cancer (NSCLC). This marks the s... |
| 16.02.2026 | CStone Announces FDA Clearance of IND Application for Its Novel Trispecific Antibody CS2009 (PD-1/VEGF/CTLA-4) to Advance into Phase II Clinical Trial | CS2009 (PD-1/VEGF/CTLA-4 trispecific antibody) has received Investigational New Drug (IND) clearance from the U.S. Food and Drug Administration (FDA) to initiate a Phase II clinical trial in patients with advanced solid tumors. This marks a... |
| 07.11.2025 | ACAAI 2025 | CS2015 (OX40L/TSLP Bispecific Antibody) Makes International Debut | SUZHOU, China, Nov. 7, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation, ... |
| 20.10.2025 | ESMO 2025: CStone Discloses Phase I Data for CS2009 (PD-1/VEGF/CTLA-4 Trispecific Antibody) | SUZHOU, China, Oct. 20, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone," HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of therapies for oncology, autoimmune/inflammation,... |
| 07.05.2025 | CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR | SUZHOU, China, May 7, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical da... |
| 27.03.2025 | CStone Pharmaceuticals Announces 2024 Annual Results and Recent Business Progress | Financial Performance: Strong Year-over-Year Improvement
- Total Revenue: RMB 407.2 million, including RMB 232.1 million in licensing and royalty income.
- Net Loss Reduction: 71.5% year-over-year improvement.
Key Product Advancements
- Sug... |
| 26.03.2025 | CStone to Showcase Five Latest Research Achievements at AACR 2025 | SUZHOU, China, March 26, 2025 /PRNewswire/ -- From April 25 to 30, 2025, the American Association for Cancer Research (AACR) Annual Meeting will take place in Chicago. CStone will showcase its latest preclinical studies on five internally d... |
| 24.03.2025 | CStone Submits Application to the European Medicines Agency for New Indication of Sugemalimab in Stage III Non-Small Cell Lung Cancer | SUZHOU, China, March 24, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Type II variation ap... |
| 24.03.2025 | China’s biotech sector is undervalued given its AI-driven opportunities: Investor | - |
| 07.03.2025 | CStone Pharmaceuticals: Pioneering New Frontiers in Cancer Treatment | CStone Pharmaceuticals is on a mission. The biopharmaceutical company, based in Suzhou, China, is reshaping the landscape of cancer treatment. With innovative therapies in the pipeline, CStone is pushing boundaries and challenging the statu... |
| 06.03.2025 | CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL | Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape.
CS5001 is also being investigated globally in a multi-center... |
| 04.03.2025 | CStone Announces First Patient Dosed in Global Multicenter Phase I Clinical Trial of CS2009, a PD-1/VEGF/CTLA-4 Trispecific Antibody | SUZHOU, China, March 4, 2025 /PRNewswire/ --CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that the f... |
| 25.02.2025 | CStone Announces Publication of GEMSTONE-303 Study Results for Sugemalimab (Cejemly®) in JAMA | Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. The GEMSTONE-303 study results support sugemalimab in combination with chemotherapy a... |
| 10.02.2025 | CStone Announces Inclusion of Cejemly® (sugemalimab) as a First-Line Combination Therapy for NSCLC in ESMO Guideline | SUZHOU, China, Feb. 10, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, today announced that its ... |
| 27.01.2025 | CStone Partners with SteinCares to Market Sugemalimab in Latin America | CStone will receive upfront, regulatory and commercial milestone payments, and book revenue from SteinCares through the supply of sugemalimab in 10 Latin American (LATAM) countries.
This marks CStone's third major global commercialization p... |
| 23.12.2024 | CStone Announces Submission of Clinical Trial Application in Australia for CS2009, an Innovative PD-1/VEGF/CTLA-4 Trispecific Antibody | SHANGHAI, Dec. 23, 2024 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies, announced today the submission... |
| 09.12.2024 | Encouraging Efficacy and Safety: CStone Presents Latest Clinical Data on CS5001 for Advanced Lymphoma at the 66th ASH Annual Meeting | CS5001 is so far the first anti-ROR1 ADC known to show clinical anti-tumor activity in both solid tumors and lymphomas. The data presented at ASH highlighted the latest safety and efficacy of CS5001 as a monotherapy for patients with advanc... |
| 31.10.2024 | CStone Announces MHRA Approval of Sugemalimab for First-Line Treatment of Non-Small Cell Lung Cancer (NSCLC) in the UK | This approval marks the second international marketing authorization for sugemalimab outside of China, following its recent approval by the European Commission.
The approval is based on results from the Phase 3 GEMSTONE-302 clinical trial, ... |
| 23.08.2024 | CStone Reports 2024 Interim Results and Recent Corporate Updates | Total revenue of RMB 254.2 million for 2024 H1; achieving first-time profitability with cash reserve at RMB 814 million as of June 30, 2024.
NDA approval of sugemalimab (PD-L1) for Stage IV NSCLC in EU, marking the first successful internat... |
| 26.07.2024 | CStone Announces European Commission Approval of Sugemalimab (Cejemly®) as First-Line Treatment for Non-Small Cell Lung Cancer | Sugemalimab becomes the world's first anti-PD-L1 monoclonal antibody (mAb) approved in Europe for first-line treatment of both squamous and non-squamous non-small cell lung cancer (NSCLC), also marking the first successful international app... |
| 02.06.2024 | CStone Announces European Medicine Agency CHMP Recommends Approval of Cejemly® (sugemalimab, anti-PD-L1) as First-Line Treatment for NSCLC | EMA CHMP recommendation is based on the results of a Phase 3 clinical trial (GEMSTONE-302) demonstrating significant progression-free survival (PFS) and overall survival (OS) benefits of sugemalimab in combination with chemotherapy as a fir... |
| 24.05.2024 | CStone Announces Abstract Release of CS5001 (ROR1 ADC) First-in-Human Clinical Data on ASCO Website | CS5001 is the first known ROR1 antibody-drug conjugate (ADC) to demonstrate clinical anti-tumor activity in both solid tumors and lymphomas, and among the top two globally in clinical development.
First-in-human study data show that CS5001 ... |
| 27.03.2024 | CStone Pharmaceuticals Reports 2023 Annual Results and Business Updates | Total revenue for 2023 was RMB463.8 million, with commercial revenue of RMB 368.1 million
Healthy financial position with cash reserves of RMB 1,026.7 million as of December 31, 2023 and net loss narrowed by 57% from the past year
CStone es... |
| 15.03.2024 | CStone Announces the Fifth Indication Approved for Sugemalimab in China as First-Line Treatment for Gastric Cancer | Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for the treatment of gastric or gastroesophageal junction (G/GEJ) adenocarcinoma.
This marks the 13th NDA approval obtained by CStone and sugemalimab's fifth indicatio... |
| 21.12.2023 | CStone sells to Servier its exclusive rights to TIBSOVO® in Greater China and Singapore | The deal enables CStone to prioritize its resources to focus on the development of first-in-class and best-in-class therapies with global rights.
The deal enables Servier to potentially bring additional indications and accessibility of TIBS... |
| 08.12.2023 | CStone Announces NMPA Approval of Sugemalimab as First-line Treatment for Esophageal Squamous Cell Carcinoma | Sugemalimab is the world's first anti-PD-L1 monoclonal antibody approved for use in combination with fluorouracil and platinum-based chemotherapy for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma.... |
| 01.11.2023 | CStone Announces Strategic Partnership and Exclusive Licensing Agreement with 3SBio for Nofazinlimab (Anti-PD-1 Antibody) in Mainland China | CStone to grant 3SBio exclusive rights for the development, registration, manufacturing, and commercialization of nofazinlimab (anti-PD-1 antibody) in mainland China. CStone to retain the rights to nofazinlimab outside mainland China.
This ... |
| 31.10.2023 | CStone Announces NMPA Approval of Sugemalimab for Patients with Relapsed or Refractory Extranodal NK/T-cell Lymphoma, the First Anti-PD-1/PD-L1 mAb Approved for this Indication | Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody approved for relapsed or refractory extranodal NK/T-cell lymphoma (R/R ENKTL) indication.
This marks sugemalimab's third indication approved in China following Stage III a... |
| 15.08.2023 | CStone Pharmaceuticals Reports 2023 Interim Results and Updates | The total revenue was RMB 261.5 million for the six months ended June 30, 2023. The sales of pharmaceutical products revenue was RMB 246.9 million, representing a growth rate of 53% compared to the same period last year. Commercial gross pr... |
| 27.06.2023 | CStone announces GAVRETO® (pralsetinib) sNDA approval by China NMPA for first-line treatment of patients with locally advanced or metastatic RET fusion-positive non-small cell lung cancer | The approval for the first-line treatment of RET fusion-positive non-small cell lung cancer marks the third indication of GAVRETO in Mainland China, and the eleventh new drug application approval that CStone has obtained in Greater China ov... |
| 15.03.2023 | CStone Pharmaceuticals Reports 2022 Annual Results and Business Updates | The total revenue for 2022 was RMB 481.4 million, with commercial revenue of RMB 394.1 million, which represents a 142% increase compared to the previous year
Healthy financial position with cash reserves of RMB 1.042 billion as of December... |
| 28.02.2023 | CStone announces China's NMPA has accepted the supplementary new drug application of sugemalimab as first-line treatment for patients with locally advanced or metastatic gastric/gastroesophageal junct... | This supplementary new drug application was filed for the fourth indication for sugemalimab in China, following applications for stage III and stage IV non-small cell lung cancer and relapsed or refractory extranodal NK/T cell lymphoma. If ... |
| 03.01.2023 | CStone announces the registrational clinical trial of sugemalimab as first-line treatment in patients with esophageal squamous cell carcinoma met primary endpoints and plans to submit a supplemental N... | Sugemalimab became the first anti-PD-L1 monoclonal antibody that achieved positive results in the study of patients with unresectable locally advanced, recurrent, or metastatic esophageal squamous cell carcinoma.
Sugemalimab in combination ... |
| 13.09.2022 | CStone announces China's NMPA has accepted and granted priority review to the supplemental new drug application (sNDA) for sugemalimab in the treatment of patients with relapsed or refractory extranod... | This is the third supplemental new drug application (NDA) that CStone has submitted for sugemalimab after the prior two for stage III and IV non-small cell lung cancer. Sugemalimab has the potential to become the world's first immuno-oncolo... |
| 25.08.2022 | CStone Pharmaceuticals Reports 2022 Interim Results and Business Updates | SUZHOU, China, Aug. 25, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and pr... |
| 15.07.2022 | CStone Announces the NDA Approval of GAVRETO® (pralsetinib) for the Treatment of RET Fusion-Positive treatment-naïve (first-line) and pretreated Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China... | GAVRETO is the first highly selective rearranged during transfection (RET) inhibitor approved in Hong Kong, China for the treatment of RET fusion-positive metastatic non-small cell lung cancer
GAVRETO is CStone's second therapy approved in ... |
| 07.06.2022 | CStone presents pre-specified overall survival data of sugemalimab for first-line treatment of stage IV non-small cell lung cancer at ASCO 2022 | Sugemalimab is the world's first PD-L1 monoclonal antibody to show the statistically significant and clinically meaningful overall survival improvement in combination with chemotherapy for patients with treatment-naïve stage IV non-small ce... |
| 05.06.2022 | CStone presents updated results of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment in patients with unresectable hepatocellular carcinoma (HCC) at ASCO 2022 | Nofazinlimab in combination with lenvatinib as first-line treatment for unresectable hepatocellular carcinoma demonstrated an objective response rate of 45.0%. The median duration of response was not yet reached as of the data cutoff date (... |
| 04.06.2022 | CStone presents clinical results of sugemalimab in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma via an oral abstract session at ASCO 2022 | GEMSTONE-201 is the largest registrational clinical study of an anti-PD-(L)1 antibody reported so far in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL).
Results on the primary endpoint showed that... |
| 01.06.2022 | CStone Pharmaceuticals Reports 2021 Annual Results and Recent Business Highlights | SUZHOU, China, June 1, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and pre... |
| 17.05.2022 | CStone announces final PFS analysis of a registrational study of sugemalimab in patients with stage III NSCLC further demonstrates its robust efficacy and significant clinical benefits shown in interi... | Sugemalimab is the world's first anti-PD-(L)1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression following concurrent or seq... |
| 28.04.2022 | CStone to present the latest clinical results of anti-PD-L1 antibody sugemalimab and anti-PD-1 antibody nofazinlimab at ASCO 2022 | Results from GEMSTONE-201 study of sugemalimab, the first successful registrational clinical study to date evaluating an anti-PD-(L)1 antibody targeting patients with relapsed or refractory extranodal natural killer/T-cell lymphoma, will be... |
| 22.04.2022 | CStone Announces Results From Phase 3 AGILE Data of TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine for Patients with Previously Untreated IDH1-mutated Acute Myeloid Leukemia Published i... | Results from the trial present a significant advancement for patients dealing with previously untreated IDH1-mutated AML
Global Phase 3 trial of TIBSOVO (ivosidenib tablets) met its primary endpoint of event-free survival and all key second... |
| 13.04.2022 | CStone Announces Presentation of Preclinical data on a Multi-Specific Antibody-based Therapeutic Candidate CS2006/NM21-1480 at the American Association for Cancer Research (AACR) Annual Meeting 2022 | Results from pharmacokinetic/pharmacodynamic modeling demonstrated that binding affinity optimization of CS2006/NM21-1480 allowed optimal PD-L1 blockade and 4-1BB stimulation concomitantly, at a broad dose range thereby and facilitating dos... |
| 31.03.2022 | CStone announces first patient enrollment in the U.S. in the Phase 1 clinical trial of CS5001, a potential global best-in-class ROR1-targeting ADC | Commencement of the first-in-human clinical trial of CS5001 marks another key milestone for CStone's Pipeline 2.0
Global development of CS5001 is conducted in the form of a multi-regional clinical trial, with sites initiated in the US and A... |
| 18.03.2022 | CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) in Hong Kong, China | SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and p... |
| 18.03.2022 | CStone announced the global multi-regional registration trial of anti-PD-1 antibody nofazinlimab in combination with lenvatinib as first-line treatment for patients with advanced hepatocellular carcin... | SUZHOU, China, March 18, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and p... |
| 14.03.2022 | CStone announces the NMPA approval of GAVRETO (pralsetinib) for the treatment of Advanced or Metastatic RET-mutant medullary thyroid cancer and RET fusion-positive thyroid cancer | GAVRETO is the first and only selective rearranged during transfection (RET) inhibitor approved in China for the treatment of RET-mutant medullary thyroid cancer (MTC) and RET fusion-positive thyroid cancer (TC)
The labeled indications of G... |
| 17.02.2022 | CStone Pharmaceuticals Announces the Acceptance of New Drug Application (NDA) for Pralsetinib for the Treatment of RET Fusion-Positive Non-Small Cell Lung Cancer (NSCLC) and RET-Altered Thyroid Cancer... | SUZHOU, China, Feb. 17, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and pr... |
| 09.02.2022 | CStone announced new drug approval of China's first IDH1 inhibitor TIBSOVO® (ivosidenib tablets) as a new precision therapy for patients with acute myeloid leukemia | TIBSOVO®, a first-in-class drug, is approved for adult patients with relapsed/refractory acute myeloid leukemia (R/R AML) who have a susceptible IDH1 mutation
Clinical study data showed that TIBSOVO® had robust clinical efficacy and a well-... |
| 19.01.2022 | CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients | Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic squamous and non-squamous non-small cell lung cancer patients in a statistically si... |
| 19.01.2022 | CStone announces the GEMSTONE-302 study of sugemalimab met the endpoint of overall survival in the first-line treatment of metastatic non-small cell lung cancer patients | Sugemalimab is the world's first PD-L1 monoclonal antibody that when administered along with chemotherapy improved overall survival of first-line metastatic squamous and non-squamous non-small cell lung cancer patients in a statistically si... |
| 18.01.2022 | CStone announced two key phase 3 registrational clinical trials of sugemalimab completed patient enrollment | Both trials investigate first-line treatment with sugemalimab combined with chemotherapy in patients with metastatic gastric adenocarcinoma (GC)/gastro-esophageal junction (GEJ) adenocarcinoma or esophageal squamous cell carcinoma (ESCC)
A ... |
| 15.01.2022 | CStone announces the clinical data from registrational study of Sugemalimab in stage III non-small cell lung cancer published in The Lancet Oncology | SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and pr... |
| 15.01.2022 | CStone announces the registrational clinical study results of sugemalimab in stage IV non-small cell lung cancer published in The Lancet Oncology | SUZHOU, China, Jan. 15, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on research, development, and commercialization of innovative immuno-oncology therapies and pr... |
| 13.01.2022 | CStone announces phase 2 GEMSTONE-201 trial met primary endpoint of objective response rate (ORR) in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL) | Sugemalimab has the potential to become the world's first immunotherapy to be approved for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL)
The National Medical Products Administration (NMPA) of Chi... |
| 03.01.2022 | CStone Pharmaceuticals announced the IND approval of CS5001, a potential global best-in-class ROR1-targeting ADC by the U.S. Food and Drug Administration | SUZHOU, China, Jan. 3, 2022 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and... |
| 28.12.2021 | CStone announced new drug approval of precision therapy AYVAKIT® (avapritinib) in Hong Kong, China for the treatment of PDGFRA D842V mutant gastrointestinal stromal tumors (GIST) | AYVAKIT is the first precision therapy approved in Hong Kong, China for the treatment of patients with PDGFRA D842V mutant GIST
This is CStone's fifth NDA approval in Greater China this year
SUZHOU, China, Dec. 28, 2021 /PRNewswire/ -- CSto... |
| 21.12.2021 | CSTONE ANNOUNCED NEW DRUG APPROVAL OF CEJEMLY® (SUGEMALIMAB) IN CHINA TO POTENTIALLY RESHAPE THE LANDSCAPE OF IMMUNO-ONCOLOGY THERAPY IN LUNG CANCER | SUZHOU, China, Dec. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals (the "Company" or "CStone") is pleased to announce that the National Medical Products Administration ("NMPA") of China has approved the new dr... |
| 12.12.2021 | Phase 3 Data Show That TIBSOVO® (ivosidenib tablets) in Combination with Azacitidine Significantly Improves Event-Free Survival and Overall Survival in Patients with Previously Untreated IDH1-mutated ... | TIBSOVO in combination with azacitidine compared to placebo plus azacitidine also demonstrated significant improvement in complete remission rate, complete remission and complete remission with partial hematologic recovery rate and objectiv... |
| 21.11.2021 | CStone Pharmaceuticals and Jiangsu Hengrui Pharmaceuticals announce strategic partnership and exclusive licensing agreement on anti-CTLA-4 monoclonal antibody CS1002 in Greater China | SUZHOU, China, Nov. 21, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies an... |
| 09.11.2021 | CStone Pharmaceuticals and DotBio sign a global discovery collaboration and option agreement to expand emerging portfolio of next-generation innovative therapeutics | The two sides will jointly develop up to three preclinical first-in-class or best-in-class next-generation antibody therapies, for which CStone would lead the design of the target combination based on the intended mechanism of action and Do... |
| 20.10.2021 | CStone received China NMPA IND acceptance for lorlatinib in Chinese patients with ROS1-positive advanced NSCLC | SUZHOU, China, Oct. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and preci... |
| 08.10.2021 | CStone presents research data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021 | SUZHOU, China, Oct. 8, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and... |
| 02.10.2021 | CStone presents ARROW study data for GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer (MTC) for the first time in a late breaking oral abstract session at the 90th A... | Primary efficacy results showed GAVRETO had robust and durable anti-tumor activity in the Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC), with a confirmed objective response rate (ORR) of 73.1%. And t... |
| 20.09.2021 | CStone presents clinical data from the China registrational bridging study on ivosidenib in patients with relapsed/refractory acute myeloid leukemia (R/R AML) with a susceptible IDH1 mutation at the 2... | The data showed that ivosidenib demonstrated clinical efficacy in the treatment of Chinese adults with R/R AML with a susceptible IDH1 mutation. And ivosidenib was well tolerated and had a manageable safety profile
In August 2021, the Natio... |
| 19.09.2021 | CStone presents preliminary results from a phase Ib study of the anti-CTLA-4 monoclonal antibody (mAb) CS1002 in combination with the anti-PD-1 mAb CS1003 in patients with advanced solid tumors at ESM... | SUZHOU, China, Sept. 19, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative cancer immunotherapies and ... |
| 17.09.2021 | CStone will present registrational clinical study data of Sugemalimab in patients with stage III non-small cell lung cancer in an oral presentation at ESMO Congress 2021 | Sugemalimab is the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or sequ... |
| 15.09.2021 | CStone received China NMPA IND approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody, marking further expansion of its Pipeline 2.0 | SUZHOU, China, Sept. 15, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies a... |
| 14.09.2021 | CStone presents updated data from registrational clinical study of sugemalimab in patients with stage IV NSCLC in an oral presentation at IASLC 2021 WCLC | Data with the longer follow-up showed that sugemalimab plus chemotherapy continued to demonstrate improvement in progression-free survival (PFS), after the primary efficacy endpoint was met at an interim PFS analysis last year
The updated d... |
| 09.09.2021 | CStone presents registrational bridging study data for GAVRETO® (pralsetinib) highlighting efficacy and safety in Chinese patients with advanced RET fusion-positive non-small cell lung cancer at IASLC... | SUZHOU, China, Sept. 9, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-oncology therapies and precis... |
| 06.09.2021 | CStone Pharmaceuticals Included in the Hong Kong Stock Connect | SUZHOU, China, Sept. 6, 2021 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616, "CStone" or the "Company"), a leading biopharmaceutical company focused on researching, developing and commercializing innovative immuno-on... |
| 02.09.2021 | CStone announces China's NMPA has accepted its new drug application for sugemalimab in the treatment of stage III NSCLC | Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to significantly improve progression-free survival (PFS) in patients with stage III non-small cell lung cancer (NSCLC) without disease progression after concurrent or... |
| 20.08.2021 | CStone Pharmaceuticals Selected as a Constituent of HSCI | SUZHOU, China, Aug. 20, 2021 /PRNewswire/ -- CStone Pharmaceuticals (HKEX: 2616, "CStone" or the "Company"), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-o... |
| 03.08.2021 | CStone announces positive registrational study of the first-in-class drug ivosidenib in Chinese patients with relapsed or refractory acute myeloid leukemia, and NDA has been accepted by the China NMPA... | Ivosidenib (TIBSOVO®, the brand name in the U.S.) is the first isocitrate dehydrogenase 1 (IDH1) inhibitor in China that has demonstrated its efficacy and manageable safety in patients with relapsed or refractory acute myeloid leukemia (R/R... |
| 08.07.2021 | CStone announces updated results for AYVAKIT(R) (avapritinib) in Chinese patients with advanced GIST at ESMO World Congress on Gastrointestinal Cancer 2021 | AYVAKIT has demonstrated significant anti-tumor activity in Chinese patients with PDGFRA D842V mutant gastrointestinal stromal tumor (GIST), and has also shown potential for the treatment of fourth-line GIST
AYVAKIT had a generally well-tol... |
| 07.07.2021 | CStone announces China NMPA acceptance of IND application for CS2006/NM21-1480, a PD-L1/4-1BB/HSA multi-specific antibody-based molecule, marking further expansion of its Pipeline 2.0 strategy | SUZHOU, China, July 7, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on the research, development, and commercialization of innovative immuno-oncology therapies and... |
| 28.06.2021 | CStone announces positive registrational study of GAVRETO® (pralsetinib) in Chinese patients with RET-mutant medullary thyroid cancer | Key efficacy data for GAVRETO showed deep and durable anti-tumor activity in Chinese patients with advanced or metastatic RET-mutant medullary thyroid cancer (MTC)
In March 2021, GAVRETO was approved by the National Medical Products Adminis... |
| 24.06.2021 | CStone announces positive GAVRETO® (pralsetinib) registrational study data for first-line treatment of advanced RET fusion-positive non-small cell lung cancer and plans to submit a new indication appl... | Key efficacy data showed that GAVRETO demonstrated deep and durable clinical activity in Chinese patients with RET fusion-positive non-small cell lung cancer (NSCLC)
CStone plans to submit new indication application to the China National Me... |
| 21.06.2021 | CStone announces first prescriptions of precision therapy GAVRETO® (pralsetinib) issued across China for the treatment of adults with locally advanced or metastatic RET fusion-positive non-small cell ... | SUZHOU, China, June 21, 2021 /PRNewswire/ -- GAVRETO® (pralsetinib), a precision therapy discovered by CStone Pharmaceuticals' partner Blueprint Medicines, had the first batch of prescriptions issued at Guangdong Province People's Hospital ... |
| 28.05.2021 | CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application | Sugemalimab becomes the world's first anti-PD-1/PD-L1 monoclonal antibody to successfully improve progression-free survival (PFS) in patients with stage III non-small-cell lung cancer (NSCLC) without disease progression after concurrent or ... |
| 12.05.2021 | CStone Announces Acceptance of New Drug Application in Hong Kong for Avapritinib for the Treatment of Adults with Unresectable or Metastatic PDGFRA D842V Mutant Gastrointestinal Stromal Tumor | SUZHOU, China, May 12, 2021 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), a leading biopharmaceutical company focused on researching, developing, and commercializing innovative immuno-oncology therapies and precis... |
| 27.02.2019 | China's CStone raises $285M in IPO; Axial raises $25M for microbiome work on Parkinson's, autism | → Targeting the axis between the gut and the brain, microbiome startup Axial has landed a $25 million B round as it looks to advance programs for Parkinson’s disease and autism. Seventure Partners, through its microbio... |
| 14.02.2019 | In HKEX's first test in 2019, CStone seeks up to $304M in IPO fortune | As the Nasdaq ushered in its first biotech unicorns of 2019 with the listings of Alector and Gossamer, CStone is kicking things off at the Hong Kong Stock Exchange with a potential $304 million (HK$2.39 billion) price tag on its... |
| 09.05.2018 | Term Sheet — Wednesday, May 9 | 5 Qs WITH A DEALMAKER
Good morning, Term Sheet readers.
Paid Content How can you protect what you can't see? From ExtraHop
It’s why she listened to Tinder’s Sean Rad when he told her he had a dating app idea. It’s why she constantly asks he... |
| 09.05.2018 | CStone Pharmaceuticals Completes $260M Series B Funding | CStone Pharmaceuticals, a Suzhou, China-based biopharmaceutical company, completed a $260m (about RMB1.65 billion) Series B funding.
The round was led by GIC Private Limited, with participation from new investors including Sequoia China, Yu... |
| 08.05.2018 | CStone Raises $260 million in Series B Financing to Advance Novel Cancer Therapies | - |
| 05.07.2016 | CStone raises $150M in Series A; gains ex-Sanofi exec as CEO | China upstart CStone Pharma has raised a major $150 million in a Series A funding drive as it looks to boost its research in immuno-oncology.
The biotech also announced that Dr. Frank Jiang, a former Sanofi ($SNY) research exec, has taken u... |
| 04.07.2016 | CStone Pharmaceuticals Closes $150M Series A Financing | CStone Pharmaceuticals Co., Ltd, a Shanghai and Suzhou, China-based biopharmaceutical company developing new treatments in a range of therapeutic areas, closed its Series A round of $150m financing (about 975m RMB).
Backers included Oriza S... |
| 03.07.2016 | CStone Pharmaceuticals Receives $150M in Series A from WuXi Healthcare | CStone Pharmaceuticals Co., Ltd (CStone), a bio-pharmaceutical company devoted to developing new treatments in a range of therapeutic areas, announced that it has closed its Series A round of 150 million dollars financing (about 975 million... |
